Research Analysts Set Expectations for Surrozen Q1 Earnings

Surrozen, Inc. (NASDAQ:SRZN) – Stock analysts at HC Wainwright upped their Q1 2025 earnings estimates for Surrozen in a report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($1.09) for the quarter, up from their prior forecast of ($2.71). HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share. HC Wainwright also issued estimates for Surrozen’s Q2 2025 earnings at ($1.07) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($4.22) EPS, FY2026 earnings at ($4.63) EPS, FY2027 earnings at ($5.50) EPS, FY2028 earnings at ($6.53) EPS and FY2029 earnings at ($7.15) EPS.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings results on Monday, March 31st. The company reported ($9.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.54) by ($6.56). The business had revenue of $0.66 million during the quarter.

Separately, Guggenheim upgraded Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price objective on the stock in a research note on Friday, January 3rd.

Surrozen Stock Down 10.8 %

Shares of NASDAQ:SRZN opened at $9.80 on Monday. The business’s 50 day moving average is $11.31 and its 200 day moving average is $11.10. Surrozen has a 12-month low of $6.00 and a 12-month high of $18.17. The stock has a market cap of $31.85 million, a price-to-earnings ratio of -0.45 and a beta of 0.69.

Institutional Investors Weigh In On Surrozen

A number of hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC increased its holdings in Surrozen by 26.1% during the fourth quarter. Geode Capital Management LLC now owns 22,391 shares of the company’s stock worth $321,000 after buying an additional 4,630 shares during the last quarter. Trustees of Columbia University in the City of New York purchased a new stake in shares of Surrozen during the 4th quarter worth approximately $688,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Surrozen during the 4th quarter worth approximately $928,000. Regents of The University of California bought a new stake in shares of Surrozen in the 4th quarter worth approximately $1,912,000. Finally, Stonepine Capital Management LLC lifted its stake in Surrozen by 24.7% in the fourth quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company’s stock valued at $1,969,000 after purchasing an additional 27,200 shares during the last quarter. 66.57% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Surrozen

In other Surrozen news, major shareholder Group Gp Lp Column III acquired 1,034,482 shares of the business’s stock in a transaction on Wednesday, March 26th. The shares were acquired at an average price of $11.60 per share, with a total value of $11,999,991.20. Following the completion of the transaction, the insider now owns 795,411 shares in the company, valued at approximately $9,226,767.60. This trade represents a -432.71 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 43.50% of the company’s stock.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.